{"nctId":"NCT04324073","briefTitle":"Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients - Sarilumab Trial - CORIMUNO-19 - SARI","startDateStruct":{"date":"2020-03-27","type":"ACTUAL"},"conditions":["Corona Virus Infection"],"count":239,"armGroups":[{"label":"SARILUMAB -- Severe COVID population (WHO Clinical Progression Scale =5 at baseline)","type":"EXPERIMENTAL","interventionNames":["Drug: Sarilumab"]},{"label":"Standard of care -- Severe COVID population (WHO Clinical Progression Scale =5 at baseline)","type":"NO_INTERVENTION","interventionNames":[]},{"label":"SARILUMAB -- Critical COVID population (WHO Clinical Progression Scale >5 at baseline)","type":"EXPERIMENTAL","interventionNames":["Drug: Sarilumab"]},{"label":"Standard of care -- Critical COVID population (WHO Clinical Progression Scale >5)","type":"NO_INTERVENTION","interventionNames":[]}],"interventions":[{"name":"Sarilumab","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Patients included in the CORIMUNO-19 cohort\n2. Patients belonging to one of the 2 following groups:\n\n   * Group 1: patients not requiring Intensive Care Unit at admission with moderate and severe pneumopathy according to the OMS Criteria of severity of COVID pneumopathy.\n\nModerate cases :\n\nCases meeting all of the following criteria:\n\n* Showing fever and respiratory symptoms with radiological findings of pneumonia.\n* Requiring between 3L/min and 5L/min of oxygen to maintain SpO2 \\>97% Severe cases\n\nCases meeting any of the following criteria:\n\n* Respiratory distress (≧30 breaths/ min);\n* Oxygen saturation≤93% at rest in ambient air; or Oxygen saturation ≤97 % with O2 \\> 5L/min.\n* PaO2/FiO2≦300mmHg\n* Group 2: patients requiring Intensive Care Unit based on Criteria of severity of COVID pneumopathy.\n* Respiratory failure and requiring mechanical ventilation\n* No do-not-resuscitate order (DNR order)\n\nExclusion Criteria:\n\n* Patients with exclusion criteria to the CORIMUNO-19 cohort.\n* Known hypersensitivity to Sarilumab or to any of their excipients.\n* Pregnancy\n* Current documented bacterial infection\n* Patient with any of following laboratory results out of the ranges detailed below at screening should be discussed depending of the medication:\n* Absolute neutrophil count (ANC) ≤ 1.0 x 109/L\n* Haemoglobin level: no limitation\n* Platelets (PLT) \\< 50 G /L\n* SGOT or SGPT \\> 5N","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With WHO Clinical Progression Scale > 5 at Day 4 -- Severe COVID Population (WHO Clinical Progression Scale =5 at Baseline)","description":"Percentage of participants who has died or needed non-invasive or mechanical ventilation by day 4 (WHO clinical progression scale \\> 5). A patient with new do-not-resuscitate order at day 4 will be considered as with a score \\> 5.\n\nWHO progression scale:\n\nUninfected; non viral RNA detected: 0 Asymptomatic; viral RNA detected: 1 Symptomatic; Independent: 2 Symptomatic; Assistance needed: 3 Hospitalized; No oxygen therapy: 4 Hospitalized; oxygen by mask or nasal prongs: 5 Hospitalized; oxygen by NIV or High flow: 6 Intubation and Mechanical ventilation, pO2/FIO2\\>=150 OR SpO2/FIO2\\>=200: 7 Mechanical ventilation, (pO2/FIO2\\<150 OR SpO2/FIO2\\<200) OR vasopressors (norepinephrine \\>0.3 microg/kg/min): 8 Mechanical ventilation, pO2/FIO2\\<150 AND vasopressors (norepinephrine \\>0.3 microg/kg/min), OR Dialysis OR ECMO: 9 Dead: 10","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26","spread":null},{"groupId":"OG001","value":"26","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With Non-invasive Ventilation, Mechanical Ventilation or Death at Day 14 (WHO Clinical Progression Scale =5 at Baseline)","description":"Survival without needs of ventilator utilization (including non invasive ventilation and high flow) at day 14. Percentage of non-invasive ventilation, mechanical ventilation or death. Thus, events considered are needing ventilator utilization (mechanical or non-invasive ventilation including high flow oxygen), or death. New do-not-resuscitate (DNR) order (if given after the inclusion of the patient) will be considered as an event at the date of the DNR.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"37","spread":null},{"groupId":"OG001","value":"34","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With no Improvement in WHO Clinical Progression Scale at Day 4 -- Critical COVID Population ( WHO Clinical Progression Scale >5 at Baseline)","description":"Results are presented as the percentage not improved, so that an effective treatment would be associated with a decrease in percentage\n\nScale:\n\nUninfected; non viral RNA detected: 0 Asymptomatic; viral RNA detected: 1 Symptomatic; Independent: 2 Symptomatic; Assistance needed: 3 Hospitalized; No oxygen therapy: 4 Hospitalized; oxygen by mask or nasal prongs: 5 Hospitalized; oxygen by NIV or High flow: 6 Intubation and Mechanical ventilation, pO2/FIO2\\>=150 OR SpO2/FIO2\\>=200: 7 Mechanical ventilation, (pO2/FIO2\\<150 OR SpO2/FIO2\\<200) OR vasopressors (norepinephrine \\>0.3 microg/kg/min): 8 Mechanical ventilation, pO2/FIO2\\<150 AND vasopressors (norepinephrine \\>0.3 microg/kg/min), OR Dialysis OR ECMO: 9","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"71","spread":null},{"groupId":"OG001","value":"79","spread":null}]}]}]},{"type":"PRIMARY","title":"Cumulative Incidence (Percentage of Participants) With Successful Tracheal Extubation at Day 14 -- Critical COVID Population (WHO Clinical Progression Scale >5 at Baseline)","description":"Cumulative incidence of successful tracheal extubation (defined as duration extubation \\> 48h) at day 14 if patients have been intubated before day 14 ; or removal of Non Invasive Ventilation or high flow (for \\> 48h) if they were included under oxygen by Non Invasive Ventilation or High flow (score 6) and remained without intubation. Death or new do-not-resuscitate order (if given after the inclusion of the patient) will be considered as a competing event.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"38","spread":null},{"groupId":"OG001","value":"33","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Surviving (Overall Survival)","description":"Percentage of participants surviving at 14, 28 and 90 days","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"91","spread":null},{"groupId":"OG001","value":"89","spread":null},{"groupId":"OG002","value":"75","spread":null},{"groupId":"OG003","value":"73","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"88","spread":null},{"groupId":"OG001","value":"82","spread":null},{"groupId":"OG002","value":"71","spread":null},{"groupId":"OG003","value":"67","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"85","spread":null},{"groupId":"OG001","value":"79","spread":null},{"groupId":"OG002","value":"71","spread":null},{"groupId":"OG003","value":"61","spread":null}]}]}]},{"type":"SECONDARY","title":"WHO Progression Scale","description":"WHO progression scale:\n\nUninfected; non viral RNA detected: 0 Asymptomatic; viral RNA detected: 1 Symptomatic; Independent: 2 Symptomatic; Assistance needed: 3 Hospitalized; No oxygen therapy: 4 Hospitalized; oxygen by mask or nasal prongs: 5 Hospitalized; oxygen by NIV or High flow: 6 Intubation and Mechanical ventilation, pO2/FIO2\\>=150 OR SpO2/FIO2\\>=200: 7 Mechanical ventilation, (pO2/FIO2\\<150 OR SpO2/FIO2\\<200) OR vasopressors (norepinephrine \\>0.3 microg/kg/min): 8 Mechanical ventilation, pO2/FIO2\\<150 AND vasopressors (norepinephrine \\>0.3 microg/kg/min), OR Dialysis OR ECMO: 9 Dead: 10","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"5","spread":null},{"groupId":"OG002","value":"7","spread":null},{"groupId":"OG003","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"5","spread":null},{"groupId":"OG002","value":"8","spread":null},{"groupId":"OG003","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"5","spread":null},{"groupId":"OG002","value":"7","spread":null},{"groupId":"OG003","value":"7","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean of Ventilator Free-days at Day 28 -- Critical COVID Population (WHO-clinical Progression Scale >5 at Baseline)","description":"28-day ventilator free-days","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.3","spread":"11.1"},{"groupId":"OG001","value":"8.7","spread":"11"}]}]}]},{"type":"SECONDARY","title":"Cumulative Incidence (Percentage of Participants) of Oxygen Supply Independency","description":"Time to oxygen supply independency","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"75","spread":null},{"groupId":"OG001","value":"71","spread":null},{"groupId":"OG002","value":"44","spread":null},{"groupId":"OG003","value":"36","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"81","spread":null},{"groupId":"OG001","value":"78","spread":null},{"groupId":"OG002","value":"71","spread":null},{"groupId":"OG003","value":"56","spread":null}]}]}]},{"type":"SECONDARY","title":"Cumulative Incidence (Percentage of Participants) of Discharge From Hospital","description":"Time to discharge from hospital","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"75","spread":null},{"groupId":"OG001","value":"70","spread":null},{"groupId":"OG002","value":"35","spread":null},{"groupId":"OG003","value":"30","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"79","spread":null},{"groupId":"OG001","value":"76","spread":null},{"groupId":"OG002","value":"65","spread":null},{"groupId":"OG003","value":"52","spread":null}]}]}]},{"type":"SECONDARY","title":"Cumulative Incidence (Percentage of Participants) of Intensive Care Unit Discharge -- Critical COVID Population (WHO Clinical Progression Scale >5 at Baseline)","description":"Time to discharge from Intensive Care Unit","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"60","spread":null},{"groupId":"OG001","value":"71","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"79","spread":null},{"groupId":"OG001","value":"82","spread":null}]}]}]},{"type":"SECONDARY","title":"PaO2/FiO2 Ratio -- Critical COVID Population (WHO-CPS >5)","description":"evolution of PaO2/FiO2 ratio PaO2 is partial pressure of arterial oxygen expressed in mmHg. FiO2 is fraction of inspired oxygen (for instance, 0.33 for 33% oxygen) with no units.\n\nPaO2/FiO2 ratio is expressed in mmHg.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"177.8","spread":null},{"groupId":"OG001","value":"106.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"143.0","spread":null},{"groupId":"OG001","value":"156.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"142.4","spread":null},{"groupId":"OG001","value":"157.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"139.8","spread":null},{"groupId":"OG001","value":"212.0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":27,"n":68},"commonTop":[]}}}